Jo Lynne Rokita

Jo Lynne Rokita

Auto-generated profile, based on publicly available information

Jo Lynne Rokita

Center for Cancer and Immunology Research, Children’s National Hospital, Washington, D.C., USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Cell
Verified
Journal Article
Open access
FPFrancesca Petralia
Francesca Petralia
NTNicole Tignor
Nicole Tignor
BRBoris Reva
Boris Reva
MKMateusz Koptyra
Mateusz Koptyra
SCShrabanti Chowdhury
Shrabanti Chowdhury
WBWilliam E. Bocik
William E. Bocik
We report a comprehensive proteogenomics analysis, including whole-genome sequencing, RNA sequencing, and proteomics and phosphoproteomics profiling, of 218 tumors across 7 histological types of childhood brain cancer: low-grade glioma (n = 93), ependymoma (32), high-grade glioma (25), medulloblastoma (22), ganglioglioma (18), craniopharyngioma (16), and atypical teratoid rhabdoid tumor (12). Proteomics data identify common biological themes that span histological boundaries, suggesting that treatments used for one histological type may be applied effectively to other tumors sharing similar proteomics features. Immune landscape characterization reveals diverse tumor microenvironments across and within diagnoses. Proteomics data further reveal functional effects of somatic mutations and copy number variations (CNVs) not evident in transcriptomics data. Kinase-substrate association and co-expression network analysis identify important biological mechanisms of tumorigenesis. This is the first large-scale proteogenomics analysis across traditional histological boundaries to uncover foundational pediatric brain tumor biology and inform rational treatment selection.

1 September 2017 in Cancer Cell
Verified
Journal Article
Closed access
KBKristopher R. Bosse
Kristopher R. Bosse
PRPichai Raman
Pichai Raman
ZZZhongyu Zhu
Zhongyu Zhu
MLMaria Lane
Maria Lane
DMDaniel Martinez
Daniel Martinez
JMJohn M. Maris
John M. Maris

30 April 2018 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
PRPresha Rajbhandari
Presha Rajbhandari
GLGonzalo Lopez
Gonzalo Lopez
CCClaudia Capdevila
Claudia Capdevila
BSBeatrice Salvatori
Beatrice Salvatori
JYJiyang Yu
Jiyang Yu
ACAndrea Califano
Andrea Califano
High-risk neuroblastomas show a paucity of recurrent somatic mutations at diagnosis. As a result, the molecular basis for this aggressive phenotype remains elusive. Recent progress in regulatory network analysis helped us elucidate disease-driving mechanisms downstream of genomic alterations, including recurrent chromosomal alterations. Our analysis identified three molecular subtypes of high-risk neuroblastomas, consistent with chromosomal alterations, and identified subtype-specific master regulator proteins that were conserved across independent cohorts. A 10-protein transcriptional module—centered around a TEAD4–MYCN positive feedback loop—emerged as the regulatory driver of the high-risk subtype associated with MYCN amplification. Silencing of either gene collapsed MYCN-amplified (MYCNAmp) neuroblastoma transcriptional hallmarks and abrogated viability in vitro and in vivo. Consistently, TEAD4 emerged as a robust prognostic marker of poor survival, with activity independent of the canonical Hippo pathway transcriptional coactivators YAP and TAZ. These results suggest novel therapeutic strategies for the large subset of MYCN-deregulated neuroblastomas. Significance: Despite progress in understanding of neuroblastoma genetics, little progress has been made toward personalized treatment. Here, we present a framework to determine the downstream effectors of the genetic alterations sustaining neuroblastoma subtypes, which can be easily extended to other tumor types. We show the critical effect of disrupting a 10-protein module centered around a YAP/TAZ-independent TEAD4–MYCN positive feedback loop in MYCNAmp neuroblastomas, nominating TEAD4 as a novel candidate for therapeutic intervention. Cancer Discov; 8(5); 582–99. ©2018 AACR. This article is highlighted in the In This Issue feature, p. 517

1 November 2019 in Cell Reports
Verified
Journal Article
Open access
JRJo Lynne Rokita
Jo Lynne Rokita
KRKomal Rathi
Komal Rathi
MCMaria F. Cardenas
Maria F. Cardenas
KUKristen A. Upton
Kristen A. Upton
JJJoy Jayaseelan
Joy Jayaseelan
JMJohn M. Maris
John M. Maris
Accelerating cures for children with cancer remains an immediate challenge as a result of extensive oncogenic heterogeneity between and within histologies, distinct molecular mechanisms evolving between diagnosis and relapsed disease, and limited therapeutic options. To systematically prioritize and rationally test novel agents in preclinical murine models, researchers within the Pediatric Preclinical Testing Consortium are continuously developing patient-derived xenografts (PDXs)-many of which are refractory to current standard-of-care treatments-from high-risk childhood cancers. Here, we genomically characterize 261 PDX models from 37 unique pediatric cancers; demonstrate faithful recapitulation of histologies and subtypes; and refine our understanding of relapsed disease. In addition, we use expression signatures to classify tumors for TP53 and NF1 pathway inactivation. We anticipate that these data will serve as a resource for pediatric oncology drug development and will guide rational clinical trial design for children with cancer.

28 March 2017 in Scientific Data
Verified
Journal Article
Open access
PDF file
JHJo Lynne Harenza
Jo Lynne Harenza
MDMaura A. Diamond
Maura A. Diamond
RARebecca N. Adams
Rebecca N. Adams
MSMichael M. Song
Michael M. Song
HDHeather L. Davidson
Heather L. Davidson
JMJohn M. Maris
John M. Maris
Neuroblastoma cell lines are an important and cost-effective model used to study oncogenic drivers of the disease. While many of these cell lines have been previously characterized with SNP, methylation, and/or mRNA expression microarrays, there has not been an effort to comprehensively sequence these cell lines. Here, we present raw whole transcriptome data generated by RNA sequencing of 39 commonly-used neuroblastoma cell lines. These data can be used to perform differential expression analysis based on a genetic aberration or phenotype in neuroblastoma (e.g., MYCN amplification status, ALK mutation status, chromosome arm 1p, 11q and/or 17q status, sensitivity to pharmacologic perturbation). Additionally, we designed this experiment to enable structural variant and/or long-noncoding RNA analysis across these cell lines. Finally, as more DNase/ATAC and histone/transcription factor ChIP sequencing is performed in these cell lines, our RNA-Seq data will be an important complement to inform transcriptional targets as well as regulatory (enhancer or repressor) elements in neuroblastoma.

3 November 2022 in Neoplasia
Verified
Journal Article
Open access
JLJena V. Lilly
Jena V. Lilly
JRJo Lynne Rokita
Jo Lynne Rokita
JMJennifer L. Mason
Jennifer L. Mason
TPTatiana Patton
Tatiana Patton
SSStephanie Stefankiewiz
Stephanie Stefankiewiz
AWAngela J. Waanders
Angela J. Waanders
Pediatric brain tumors are the leading cause of cancer-related death in children in the United States and contribute a disproportionate number of potential years of life lost compared to adult cancers. Moreover, survivors frequently suffer long-term side effects, including secondary cancers. The Children's Brain Tumor Network (CBTN) is a multi-institutional international clinical research consortium created to advance therapeutic development through the collection and rapid distribution of biospecimens and data via open-science research platforms for real-time access and use by the global research community. The CBTN's 32 member institutions utilize a shared regulatory governance architecture at the Children's Hospital of Philadelphia to accelerate and maximize the use of biospecimens and data. As of August 2022, CBTN has enrolled over 4700 subjects, over 1500 parents, and collected over 65,000 biospecimen aliquots for research. Additionally, over 80 preclinical models have been developed from collected tumors. Multi-omic data for over 1000 tumors and germline material are currently available with data generation for > 5000 samples underway. To our knowledge, CBTN provides the largest open-access pediatric brain tumor multi-omic dataset annotated with longitudinal clinical and outcome data, imaging, associated biospecimens, child-parent genomic pedigrees, and in vivo and in vitro preclinical models. Empowered by NIH-supported platforms such as the Kids First Data Resource and the Childhood Cancer Data Initiative, the CBTN continues to expand the resources needed for scientists to accelerate translational impact for improved outcomes and quality of life for children with brain and spinal cord tumors.